Inhibitor-Based Cancer Therapy: How Community Pharmacists Can Optimize Care


In order for the immune system to effectively attack foreign cells, it relies on “checkpoints”—molecules on certain immune cells that activate (or inactivate) before initiating a response. Attend this session to hear experts in the field briefly review the immunology and pathways targeted by immune checkpoint inhibitors. They’ll also dive deep into related complications and present opportunities for community pharmacists to optimize care for patients receiving checkpoint inhibitor–based cancer therapy. 


Pharmacist Learning Objectives

At the completion of this application-based activity, participants will be able to: 

  1. State the mechanism of action of immune checkpoint inhibitors. 
  2. Describe common symptoms associated with the use of immune checkpoint inhibitors.  
  3. Discuss the appropriate steps a community pharmacist can take when encountering a patient receiving checkpoint inhibitor–based therapy who is exhibiting symptoms consistent with therapy complications. 
Daniel Zlott, PharmD, BCOP
Vice President, Professional Education Resources
American Pharmacists Association
Tricia Schneider, PharmD, MBA
Clinical Pharmacy Manager, Weinberg & Viragh Outpatient Pharmacies
Johns Hopkins Home Care Group
Learning Level: Level 1
Track: Health-System Pharmacy
Session Time Slot(s): 
Friday, March 20
10:00 AM - 11:30 AM
Gaylord National Resort - National Harbor 4-5
ACPE Pharmacist: 0202-0000-20-041-L01-P
CEUs Pharmacist: 0.15
Activity Type: